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 During the past decade, peripheral tissue dendritic cells
(DC) have been credited as the principal antigen-presenting
cells (APC) in activating naïve T cells within secondary lym-
phoid tissues (e.g., lymph nodes [LN]) [1]. As such, DC are
critical in immune surveillance in infectious diseases, cancer,
transplantation, and allergy. Recent data from our laboratory
have revealed that mature DC in the inflamed cornea, includ-
ing both resident cells and those recruited from the vascular-
ized areas around the cornea, including the limbus and con-
junctival lymphatics, traffic to draining LN through the affer-
ent lymphatics. Mature DC that express high levels of major
histocompatibility complex (MHC) class II and B7 (CD80/
CD86) costimulatory molecules can thus stimulate naïve T
cells in the draining LN to induce immunogenic inflamma-
tion [2-5]. Disruption of this eye-LN axis (e.g., through surgi-
cal cervical and submandibular lymphadenectomy) has been
shown to lead to both complete abrogation of host
allosensitization and universal and indefinite allograft survival
[6]. Therefore, determining the regulatory mechanisms of DC
trafficking is a key issue in corneal immunology. Recently,
we have been interested in using molecular strategies to
nonsurgically sever the APC-lymphatic access, an approach
we have termed “molecular lymphadenectomy”.
Our previous work has shown that signaling through vas-
cular endothelial growth factor receptor-3 (VEGFR-3) is criti-
cal for DC access to lymphatics, and that selective blockade
of this can impair DC flow to draining LN and induction of
alloimmunity [7,8]. However, VEGFR-3-based interventions
have effects beyond APC trafficking: Sprouting blood and lym-
phatic vessels express VEGFR-3, and blockade of VEGFR-3
can eventually also alter hemangiogenic and lymphangiogenic
responses [9]. Additionally, corneal epithelial VEGFR-3 has
recently been shown to be an important “sink” mechanism for
VEGF-C/D, suppressing their ligation of VEGFR-2, and hence
angiogenesis [10]. Therefore, VEGFR-3 targeting is not wholly
specific to APC trafficking. Thus, we have continued our search
for other molecular mechanisms involved in regulation of DC
trafficking.
CC chemokine receptor 7 (CCR7) is a receptor thought
to be critical for the colocalization of mature DC and T cells
in the local draining LN in several tissues [11-18]. Both CCR7
ligands, CCL19 (also known as macrophage inflammatory
protein 3-β, MIP-3β), and CCL21 (also known as secondary
lymphoid tissue chemokine, SLC), are expressed in the T-cell
zones of secondary lymphoid organs. In addition, CCL21 is
expressed by endothelial cells in lymphatic vessels and high
endothelial venules [19,20]. Therefore, CCR7-mediated DC
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Purpose: Trafficking of corneal antigen-presenting cells (APC) to draining lymph nodes (LN) is critical in triggering
immune responses. However, very little is known about the molecular regulation of this pathway. We investigated the
expression and function of the chemokine receptor CCR7 in mediating corneal APC migration in inflammation.
Methods: Expression of CCR7 and its ligands, CCL21 and CCL19, in the normal and inflamed corneas was analyzed by
RT-PCR and immunofluorescence staining. The phenotype of CCR7-expressing cells was identified by double-staining
with different cell surface markers. To trace the trafficking of APC to draining LN, we injected corneal grafts with Alexa488-
conjugated ovalbumin (OVA) and transplanted to syngeneic recipients. CCR7 expression on the Alexa488-conjugated
OVA+ cells in the ipsilateral draining LN was analyzed by flow cytometry. To determine the functional role of CCR7, we
injected anti-CCL21 neutralizing antibody subconjunctivally after corneal transplantation and analyzed changes in num-
bers of OVA+ cells in the draining LN. Each experiment was repeated at least three times.
Results: Both CCR7 and its ligand CCL21 were significantly upregulated in inflamed corneas as measured by RT-PCR
and immunofluorescence staining. CCR7+ cells were detected especially in the corneal periphery near LYVE-1+ lym-
phatic vessels. CCR7+ cells were universally CD11b+CD11c+, and a majority were major histocompatibility complex class
II positive, suggesting a monocytic dendritic cell lineage and a relative state of maturation. Forty-eight h after syngeneic
transplantation with OVA-loaded grafts, CCR7 expression was detected on the OVA+ cells in both the host corneal beds
and the draining LN. Local administration of anti-CCL21 led to a significant suppression in the flow of OVA+CD11c+ cells
to the draining LN.
Conclusions: These data suggest that in inflammation, APC expressing CCR7 on their cell surface interact with CCL21 to
facilitate their migration from the cornea to draining LN via afferent lymphatics.
Correspondence to: Dr. M. Reza Dana, Schepens Eye Research In-
stitute, Department of Ophthalmology, Harvard Medical School, 20
Staniford Street, Boston, MA, 02114; Phone: (617) 912-7404; FAX:
(617) 912-0117; email: reza.dana@schepens.harvard.edu
626migration, guided by CCL19 and CCL21, results in accumu-
lation of mature DC in the afferent lymphatics and the T-cell
areas of draining LN. Studies in CCR7-deficient mice have
revealed a marked defect in DC migration to LN and impaired
primary immune responses [11,18]. However, the expression
and function of CCR7 and their ligands in the inflamed cor-
nea have not been reported to date. We therefore hypothesized
that CCR7 and its ligands are essential for DC migration from
the cornea to the draining LN.
The specific aim of this study was to examine the expres-
sion of CCR7 and its ligands in the inflamed cornea, and de-
termine their effect on DC trafficking from the inflamed cor-
nea to the draining LN using an OVA-loaded corneal graft
model. The results demonstrated that migration of DC is fa-
cilitated by the interaction of the CCR7 expression on their
surface with CCL21 secreted by the lymphatic vessels.
METHODS
Animals:  Six- to eight-week-old male BALB/c (Taconic
Farms, Germantown, NY) mice were used in all experiments.
The animals were anesthetized with a Katamine (120 mg/Kg
BW) and Xylazine (20 mg/Kg BW) mixture before all surgi-
cal procedures. Carbon dioxide inhalation was applied to
euthanize the animal before we harvested cornea and LN. All
experimental protocols were approved by the Schepens Eye
Research Institute Animal Care and Use Committee, and all
animals were treated according to the Association for Research
in Vision and Ophthalmology statement for the Use of Ani-
mals in Ophthalmic and Vision Research.
Suture-induced inflamed cornea:  Three interrupted su-
tures (11-0 nylon, Sharpoint; Vanguard, Houston, TX) were
placed intrastromally with two stromal incursions extending
over 120° of the corneal circumference. This procedure has
been demonstrated to induce inflammatory corneal
neovascularization, also associated with significant
lymphangiogenesis [21]. After 10 days, when all corneas de-
veloped extensive neovascularization, all sutures were re-
moved. Then corneas were carefully dissected by Vannas scis-
sors around limbus for RNA isolation and immunohistochemi-
cal studies, to ensure that the conjunctival and iris tissues were
not included.
RNA isolation and reverse transcriptase-PCR:  Corneas
were harvested from the normal and inflamed mouse groups.
Five corneas were involved in each group. To further dissect
corneal epithelial and stromal-endothelial layers, another 5
corneas from inflamed mice were used. Each experiment was
repeated three times. To extract mRNA from corneal epithe-
lial and stroma-endothelial layers separately, five intact cor-
neas were placed in 30 µl of RNA stabilization reagent
(RNAlater, Qiagen, Valencia, CA) and then incubated in 250
µl of 20 mM EDTA (pH 7.4) at 37 °C for 30 min. Before
mRNA isolation, the epithelial layers were peeled away from
the stroma-endothelial layers. A combined method for total
RNA isolation was employed, using Trizol (Invitrogen Corp.,
Carlsbad, CA) for tissue homogenization on ice, precipitation
of RNA in the aqueous phase using 70% ethanol, followed by
subsequent extraction and purification using RNeasy MinElute
Spin Columns (Qiagen). Reverse transcription of total RNA
was conducted using oligo(dT)15 primer and Sensiscript Re-
verse Transcriptase (Qiagen, Hilden, Germany). PCR was
conducted using primer pairs for CCR7 (sense GAG GAA
AAG GAT GTC TGC CAC G, antisense GGC TCT CCT TGT
CAT TTT CCA G, 284 bp), CCL21 (sense CCA AGT TTA
GGC TGT CCC ATC, antisense GGG CTA CTG GGC TAT
CCT CT, 257 bp), CCL19 (sense CCT TCC GCT ACC TTC
TTA ATG, antisense CTT CTG GTC CTT GGT TTC CTG,
229 bp), CXCR3 (sense CGC AAC TGT GGT CGA GAA
AGC, antisense CAC AGG GAT GGC TGA GTT CTA C, 525
bp) and GAPDH (sense GAA GGG CAT CTT GGG CTA
CAC, antisense GCA GCG AAC TTT ATT GAT GGT ATT,
373 bp). The PCR conditions were 35 cycles at 95 °C for 30 s,
58 °C for 30 s, and 72 °C for 1 min, followed by final exten-
sion at 72 °C for 10 min. The size of PCR products was deter-
mined by agarose gel electrophoresis.
Immunohistochemical studies:  Full thickness corneal tis-
sue or 8 µm frozen sections were fixed in 4% paraformalde-
hyde for 30 min at 4 °C or acetone for 15 min at room tem-
perature (RT; n=5 per group per experiment, repeated three
times). To prevent nonspecific staining, anti-FcR mAb (CD16/
CD31, FcγIII/II receptor) and streptavidin/biotin blocking so-
lutions (Vector Laboratories, Burlingame, CA) were used to
block sections before they were stained with primary antibod-
ies or isotype-matched control antibodies at 4 °C overnight.
Thereafter, the tissues were incubated with secondary anti-
bodies at RT. For visualization of CCR7 staining, tyramide
amplification was used according to the manufacturer’s in-
structions (PerkinElmer Life Sciences, Boston, MA). Each step
was followed by three thorough washings in PBS for 5-10
min. Finally, the samples were covered with mounting me-
dium (Vector Laboratories) and analyzed by confocal laser
scanning microscope (TCS 4D; Leica, Heidelberg, Germany)
or epifluorescence microscope (Eclipse E800; Nikon, Tokyo,
Japan). The following antibodies were used: FITC-conjugated
mouse antimouse Iab (MHC class II), FITC-conjugated rat
antimouse CD11b (a marker for granulocytes, monocytes, and
macrophages), purified hamster antimouse CD11c (DC
marker), biotin-conjugated rat antimouse CCR7 (eBioscience,
San Diego, CA), biotin-conjugated goat antimouse CCL21
(R&D Systems, Minneapolis, MN), biotin-conjugated goat
antimouse CCL19 (R&D Systems), and purified rabbit
antimouse LYVE-1 (Abcam, Cambridge, MA). The second-
ary antibodies were Cy5-conjugated goat antihamster IgG
(Jackson ImmunoResearch, West Grove, PA), Cy3-conjugated
antibiotin IgG (Jackson ImmunoResearch), and FITC-conju-
gated donkey antirabbit IgG (Santa Cruz Biotechnology, Santa
Cruz, CA). Isotype controls included FITC-conjugated mouse
IgG2a, FITC-conjugated rat IgG2b, biotin-conjugated rat
IgG2a, biotin-conjugated goat IgG (Santa Cruz Biotechnol-
ogy), and purified rabbit IgG (Santa Cruz Biotechnology).
Except where noted, primary antibodies and isotype-matched
were purchased from BD Pharmingen (San Diego, CA).
Syngeneic transplantation with ovalbumin-loaded corneal
tissue:  Fluorescently labeled antigens are useful for detecting
the migration of macrophages and DC in the eye [22,23]. In
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627our study, we injected Alexa488-labeled OVA into corneal
grafts to track their migration (n=6 per experiment, repeated
three times). Intrastromal injection with 2 µl of 2 µg OVA-
Alexa488 (Molecular Probes, Eugene, OR) dissolved in PBS,
or PBS alone, was performed in BALB/c mice through the
limbus toward the central cornea, using a previously described
technique [24,25]. Briefly, a small tunnel from the corneal epi-
thelium to the anterior stroma was created using a 33-gauge
needle (Hamilton Company, Reno, NV). Another 33-gauge
needle attached to a 10 µl Hamilton syringe was passed through
the tunnel into the stroma for the injection. After 24 h, these
OVA-loaded grafts were placed onto neovascularized BALB/
c host corneal beds. Our experiments employed a method of
orthotopic corneal transplantation described in reference [26].
Briefly, a 2 mm corneal button was excised from the donor
animal and grafted onto a 1.5 mm recipient corneal bed. Eight
11-0 interrupted nylon sutures were placed to secure the graft.
Syngeneic corneal grafts never undergo immune rejection.
Ocular administration of anti-CCL21:  BALB/c mice
were randomized to receive either anti-CCL21 (R&D systems)
or isotype control goat IgG (Jackson ImmunoResearch) by
subconjunctival injection in a masked fashion (n=3 per group
per experiment, repeated three times). The antibodies were
administered at a dose of 10 µg/10 µl per mouse on day -1, 0,
1 of corneal transplantation [12,27].
Flow cytometry:  Cells were harvested and pooled from
ipsilateral submandibular LN of BALB/c recipients (n=3 per
group per experiment, repeated three times) at 48 h
posttransplantation. Upon blockade by anti-FcR mAb, cells
were labeled with PE-conjugated anti-CD11c (BD
Pharmingen) and quantified. Staining for CCR7 was done with
a chimeric CCL19-Fc fusion protein (eBioscience), with PE-
conjugated antihuman IgG (Fc-specific, eBioscience). Cells
were subsequently washed and analyzed using an Epics XL
flow cytometer (Beckman Coulter, Fullerton, CA). The per-
centage of cell subpopulations was quantified by three mea-
surements, and the average was recorded. The percentage of
OVA+ CD11c+ cells in the total cells of the draining LN was
calculated with respect to isotype control staining. Mean val-
ues for each group (n=3) were compared via a two-tailed
Student’s t-test (GraphPad Prism 4.0c, San Diego, CA). A p-
value <0.05 was considered significant.
RESULTS
CCR7 is expressed in the inflamed cornea:  We initially in-
vestigated the expression of CCR7 in both the inflamed and
the normal cornea by RT-PCR. CCR7 mRNA was detected in
the inflamed cornea, but was absent in the normal cornea (Fig-
ure 1A). Further examination of the inflamed cornea revealed
CCR7 mRNA in the stroma-endothelial layer, but not the epi-
thelial layer (Figure 1B). Consistently, CCR7+ cells were
shown by immunohistochemistry to localize only in the in-
flamed anterior corneal stroma (Figure 1C).
CCR7+ cells in the inflamed corneal stroma represent bone
marrow-derived dendritic cells:  Our previous studies have
shown that the inflamed corneal stoma is endowed with bone
marrow-derived DC and macrophages in addition to
keratocytes [3]. We used several antibodies to identify the
CCR7+ cells and to characterize the cells in the corneal stroma
that express this receptor. When double-staining was performed
for CCR7 and CD11c in whole mount corneas, we found that
CCR7+ cells were uniformly CD11c+ and mostly located in
the peripheral cornea and limbus (Figure 2B). In addition,
double-staining for CCR7 and CD11b indicated that the CCR7+
cells were also uniformly CD11b+ (Figure 2A). This is consis-
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Figure 1. CCR7 is expressed in the inflamed corneal stroma.  CCR7
expression in the cornea was first tested by RT-PCR. Lymph nodes
served as a positive control. CCR7 mRNA expression was only de-
tected in the inflamed cornea and not the normal one (A), and further
identified in the stroma-endothelial layer (B: str indicates the stro-
mal layer and endo designates the endothelia layer). CCR7 expres-
sion was displayed in red and the nuclear stain DAPI in blue on the
cross-sections of the inflamed cornea (C). In the panels, Ep indicates
corneal epithelium and St designates corneal stroma. Epifluorescence
microscopy, original magnification: X40.
628tent with our previous findings that the corneal stromal DC
were CD11b+ and of a monocytic lineage [2,3,25].
To characterize the maturational state of the CCR7+ stro-
mal DC, we further performed double-staining for CCR7 and
MHC class II. The majority of CCR7+ cells were MHC class
II positive (Figure 2C). These results indicate that CCR7 is
expressed by relatively mature CD11b+ and CD11c+ DC in
the inflamed corneal stoma. In contrast, immature DC in the
normal corneas did not express CCR7 (Figure 2F).
CCR7 is expressed by the ovalbumin-presenting dendritic
cells migrating from the cornea to the draining lymph nodes:
We assessed the migration of the CCR7+ corneal stromal DC
in syngeneic OVA-Alexa488-loaded corneal grafts (Figure
3A). Once APC pick up these fluorescence-labeled OVA anti-
gens in the corneal graft and present them on the cell surface,
these APC can be detected by their green fluorescence. Forty-
eight hours after OVA-loaded corneal grafts were transplanted
onto syngeneic lymphatic-rich host corneal beds, we found
fluorescence-labeled OVA picked up by CCR7+ cells (Figure
3B). These OVA+ cells expressed both CCR7 and CD11c on
their cell surface as measured by flow cytometry (Figure 3D).
These data confirmed that antigen-presenting DC egress from
the cornea to the draining LN with persistent expression of
CCR7 on their cell surface.
CCL21 is expressed in the inflamed corneal stroma:  We
first detected that CCL21 was significantly expressed in the
inflamed cornea at mRNA level. However, CCL19 transcript
was present only at a low level in the inflamed cornea. Addi-
tionally, CXCR3, another receptor for CCL21, was detected
neither in the normal nor the inflamed cornea (Figure 4A).
Immunohistochemical studies revealed that CCL21
colocalized with LYVE-1+ (lymphatic vessel endothelial re-
ceptor 1) lymphatics in the inflamed corneal stroma. Further-
more, dendritiform CCR7+ cells and CCL21+ cells were lo-
cated around LYVE-1+ lymphatics. However, no CCL19+ cells
were detected (Figure 4B).
CCL21 blockade inhibits corneal dendritic cell traffick-
ing to draining lymph nodes:  To test the hypothesis that cor-
neal DC trafficking is functionally effected by the interaction
of CCR7 and CCL21, we blocked local CCL21 function via
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Figure 2. CCR7 was expressed by CD11b+ and CD11c+ cells in inflamed corneal stroma.  CD11b (left), CD11b (left), CD11c (middle), and
major histocompatibility complex (MHC) class II (right) were displayed in green in the normal and inflamed whole-mounted stromas. CCR7+
cells (red) were only detected in the inflamed (top panels), not the normal (bottom panels) corneal stromas. These cells were costained with
CD11b (yellow; A) and CD11c (yellow; B). A majority of CCR7+ cells also co-expressed MHC class II (yellow; C). Confocal microscopy,
original magnification: X40.
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Figure 3. CCR7 was expressed on OVA+ cells in both the recipient corneal beds and the draining lymph nodes.  OVA-loaded corneal grafts
were transplanted into vascularized syngeneic recipient beds (A). After 48 h, a portion of CCR7+ cells (red) also expressed OVA (green) on
their surface in the recipient stromal beds (costained as yellow). Confocal microscopy, original magnification: X40 (B). Draining lymph node
(LN) cells were harvested and OVA+ cells were detected by flow cytometry. Mice with PBS-loaded corneal grafts served as negative controls
(C). Flow cytometric expression of CD11c and CCR7 on the OVA+ cells in the draining LN is shown in D.
630subconjunctival injection of anti-CCL21. Forty-eight h after
transplantion of OVA-loaded corneal grafts to syngeneic host
beds, total cells of the draining LN were harvested from either
anti-CCL21 or isotype control IgG administration group. Com-
pared with the isotype control IgG group, the group that re-
ceived subconjunctival anti-CCL21 demonstrated 40% less
OVA+CD11c+ cells in the draining LN (p <0.05; Figure 5).
DISCUSSION
 Investigation of the molecular regulation of DC trafficking is
critical for a better understanding of corneal immunity. How-
ever, the mechanisms that regulate APC egress from the cor-
nea have not been well understood, although the critical mo-
lecular mechanisms that regulate APC infiltration into the in-
flamed cornea have been much more extensively studied. Simi-
lar to other inflamed tissues, the expression of inflammatory
cytokines (IL-1 and TNF-α) and inflammatory chemokine
receptors (CCR1, CCR2, CCR3, CCR5, and CXCR1) is in-
volved first in recruitment of innate immune cells (e.g., PMNs),
and later MHC class II-positive APC (including DC, Langer-
hans cells, monocytes, and macrophages) from the intravas-
cular compartment and peripheral matrix (limbus) into the
cornea, through coordinated upregulation of endothelial cell
adhesion factors in the limbal vasculature [28-33]. It is gener-
ally accepted that the mobilization of DC from the periphery
to the LN is regulated by the gatekeeper receptor CCR7, along
with the maturation of DC [11-20]. However, studies of CCR7-
mediated DC migration from the cornea to the draining LN
are lacking. In this study, we identified CCR7 expression on
CD11b+ and CD11c+ DC in inflamed anterior corneal stroma.
In our syngeneic OVA-loaded corneal graft model, both host
and graft-derived DC were involved in antigen presentation.
CCR7 expression on these DC was found either in the host
beds or in the draining LN, indicating persistent CCR7 ex-
pression on these antigen-presenting cells during their traf-
ficking. These data suggest that CCR7 expression is highly
relevant to DC trafficking from the inflamed cornea to drain-
ing LN. Recent data suggest that CCR7 signaling may also be
relevant for inhibiting mature DC apoptosis [34], but as of yet
we have no data on this for the eye.
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Figure 4. CCR7 and CCL21 were expressed around neo-lymphatic
vessels in the vascularized corneas.  Transcript of CCL21, but not
CCL19 or CXCR3, was significantly expressed in the inflamed cor-
neas. Lymph nodes served as positive control (A). In the inflamed
corneal stromas, dendritiform CCR7+ cells (left, red) and CCL21+
cells (middle, red) were near the LYVE-1+ lymphatics (green). CCL21
also co-localized with LYVE-1+ lymphatics (middle, yellow). No
CCL19+ cells were detected (right; B). Confocal microscopy, origi-
nal magnification: X40.
631Despite studies showing that CCR7 expression typically
correlates with the upregulation of MHC and costimulatory
molecule expression during DC maturation [9,13,14,35] there
are stimuli, such as DNAX-activation protein 12 (DAP12),
that can induce CCR7 expression by DC independently of their
maturation and acquisition of MHC class II [36,37]. In our
study, we found a small portion of MHC class II-negative
CCR7+ cells, although the majority of CCR7+ cells were co-
localized with MHC class II in the inflamed cornea. These
relatively immature CCR7+ DC may have two different fates:
(1) they may complete their maturation process under further
maturation signals provided by CCL19 and CCL21 [38]; or
(2) they may migrate into the draining LN in an immature
state. Immature CCR7+ DC most likely will be poor in stimu-
lating T cells and hence may induce immune tolerance [39].
Thus, the relationship between CCR7-mediated corneal DC
trafficking and immune stimulation or tolerance induction is
worthy of further study.
Although the cornea is lymphatic-free, lymphatic vessels
can readily grow into it upon inflammatory stimulation [33].
Access of APC to the ipsilateral submandibular LN is facili-
tated by both these neolymphatic vessels in the corneal matrix
and the normally present conjunctival lymphatics [4]. Our find-
ing of CCR7+ DC close to CCL21+ and LYVE-1+ lymphatics
suggests that CCL21-CCR7 interactions promote DC access
to the lymphoid compartments. Moreover, the inhibitory ef-
fect of CCL21 blockade on antigen-bearing DC trafficking
strongly supports the hypothesis that CCL21, secreted by lym-
phatic endothelial cells, promotes CCR7+ cell migration into
the afferent lymphatics enroute to draining LN.
Another ligand of CCR7 is CCL19, which is expressed
by mature DC and stromal cells in the T cell zone of LN [40-
43]. Although we only detected CCL19 mRNA (but not pro-
tein) expression levels in the inflamed cornea, this does not
necessarily refute the contribution of CCL19 to corneal DC
trafficking. This ligand may regulate DC trafficking after these
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Figure 5. CCL21 blockade inhibited OVA+CD11c+
dendritic cell trafficking to the draining lymph nodes.
Forty-eight h after syngeneic OVA-loaded corneal
grafts were transplanted, recipient draining LN cells
were harvested from either anti-CCL21 or isotype
control IgG-treated groups. The percentage of CD11c+
and OVA+ cells was analyzed by two-color flow
cytometry (A). The results are expressed as the mean
percentage of CD11c+ and OVA+ cells±SEM of 3 mea-
surements (the asterisk indicates a p <0.05). The p-
value is determined using a two-tailed Student’s t-
test. The data are representative of three independent
experiments (B).
632cells migrate into the lymphatics or in the LN. However, we
were not able to detect this in our experiments, and conclude
that the function of CCL19, at least as it pertains to corneal
DC trafficking, is not significant.
One of the main challenges in immune modulation is to
separate suppression of innate immunity that is critical for im-
mediate host responsiveness to pathogens from T cell-medi-
ated adaptive immunity that plays a critical role in the chronic
destructive responses seen in a wide range of conditions, in-
cluding transplant rejection and various forms of viral kerati-
tis. One strategy that could potentially allow for this differen-
tial suppression of adaptive versus innate immunity is to de-
vise interventions that specifically block egress of APC from
the cornea to lymphoid reservoirs, but could leave intact the
ingress of innate cells into the cornea. Our data here, demon-
strating the role of CCR7 in regulating corneal DC trafficking
to lymphoid tissues, suggest that CCR7 and CCL21 blockade
could potentially offer one such venue for inhibiting the in-
duction of T cell-mediated immunity. Obviously, this approach
has more therapeutic benefit than surgical lymphadenectomy,
as we described previously [6], to achieve immunologic igno-
rance. In our studies, however, CCL21 blockade only demon-
strated up to 40% inhibitory effect on DC trafficking, similar
to the inhibitory effect of CCL21 blockade on skin DC [11],
suggesting that CCR7 may not be the exclusive mediator of
DC migration from the cornea to lymphoid tissues. Further
studies are necessary to determine the precise (overlapping,
additive, or synergistic) relationship of VEGFR-3 and CCR7-
mediated DC trafficking. Interestingly, CCL21 and VEGF-C,
the ligands of CCR7 and VEGFR-3, respectively, are both
expressed on lymphatic endothelia, suggesting a close rela-
tionship between DC trafficking and lymphangiogenesis in
corneal inflammation.
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